Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study

作者：Claudio Bonifati, Serena Lembo, Antonio Giovanni Richetta, Marco Romanelli, Francesca Satolli, Monica Corazza, Laura Atzori, Claudia Lasagni, Concetta Potenza, Paola Savoia, Federico Bardazzi, Vito Di Lernia, Luca Bianchi, Gabriella Fabbrocini, Claudia Giofrè, Leonardo Zichichi, Claudio Guarneri, Sabatino Pallotta, Maria Concetta Fargnoli, Francesco Loconsole, Annamaria Offidani, Martina Burlando, Stefano Piaserico, Ketty Peris, Manuela Papini, Carlo Giovanni Carrera, Antonio Costanzo, Francesca Prignano, Maria Rita Bongiorno, Paolo Dapavo, Luca Stingeni, Massimo Donini, Giuseppe Micali, Franco Rongioletti, Giuseppe Stinco, Talia Gramiccia, Giulia Cantini, Giuseppe Argenziano · 发表于：Journal of the European Academy of Dermatology and Venereology · 年份：2024 · DOI：10.1111/jdv.20187 · 被引用次数：11 · 研究领域：Psoriasis: Treatment and Pathogenesis、Spondyloarthritis Studies and Treatments、Dermatology and Skin Diseases

BACKGROUND: Facial (FP) and genital psoriasis (GP) significantly affect patients' quality of life. Despite the advances in treatments, limited data on efficacy and safety are available on these difficult-to-treat areas. Guselkumab is an interleukin (IL)-23 inhibitor which has been proven effective in treating patients with moderate-to-severe plaque psoriasis. OBJECTIVES: The aim of this interim analysis was to report the efficacy and safety of guselkumab in the treatment of patients with FP and/or GP. MATERIALS AND METHODS: GULLIVER is a 52-week Italian observational study to evaluate the effectiveness and safety of guselkumab in a real-life setting in patients with FP and/or GP. Adult patients with facial and/or genital moderate-to-severe psoriasis (sPGA score ≥ 3) were included. The primary endpoint of this analysis was the percentage of patients achieving a facial or genital sPGA score of 0 (clear) or 1 (almost clear), at Week 12. The change in the score of the facial or genital sPGA components in patients with a score ≥3 for each sPGA component was assessed. PASI score in patients with a baseline PASI above or below 10 was evaluated. RESULTS: Overall, 351 patients were included in the study; 83.3% of FP and 76.5% of GP patients achieved the primary endpoint. Similar response rates were observed for the facial or genital sPGA components in patients with a baseline facial or genital sPGA score ≥3 in each component. Among patients with a baseline PASI score >10, mean PASI sc...